Literature DB >> 33239375

Dynamics of Hepatitis E Virus (HEV) Antibodies and Development of a Multifactorial Model To Improve the Diagnosis of HEV Infection in Resource-Limited Settings.

Jie Lu1, Yan Huang1, Peiyun Wang1, Qing Li1, Ziqiang Li1, Jiayuan Jiang2, Qing Guo1, Honglian Gui3, Qing Xie3.   

Abstract

Serological markers are important for the diagnosis of hepatitis E virus (HEV) infection. This study aims to compare the diagnostic performance of the anti-HEV IgM and the HEV antigen (Ag) assays and establish a multifactorial model to improve the diagnosis of current HEV infection when HEV RNA detection is not available. A total of 809 serum samples, including 325 anti-HEV IgM-positive and 484 anti-HEV IgM-negative samples, were tested for HEV RNA. The anti-HEV IgM assay had very high sensitivity (99.4%) but moderate accuracy (79.2%) and specificity (74.3%). By retrospective follow-up of 58 patients with sequential samples (n = 143) tested for anti-HEV antibodies, we found anti-HEV IgM remained positive for more than 10 months in some HEV-infected patients, when HEV RNA was already undetectable; thus, decision solely based on anti-HEV IgM may lead to misdiagnosis. In contrast, the HEV Ag assay had very high specificity (100%). However, the detection efficiency of HEV Ag greatly diminished when the HEV RNA level was low or the anti-HEV IgG level was high. By logistic regression, a model integrating anti-HEV IgM, alanine aminotransferase, and HEV Ag was proposed, and the cutoff value was determined based on the testing results of the 143 sequential samples. The model was further evaluated with 67 randomly selected IgM-positive samples from single-visit patients. Overall, the model outperformed the anti-HEV IgM or the HEV Ag assay in the diagnosis of current HEV infection (sensitivity/specificity/accuracy, 89.5%/95.2%/91.9%). The area under the receiver operating characteristics curve of the model was greater than 0.97.
Copyright © 2021 American Society for Microbiology.

Entities:  

Keywords:  HEV Ag; IgM; diagnosis; dynamics; hepatitis E; logistic regression

Year:  2021        PMID: 33239375      PMCID: PMC8111123          DOI: 10.1128/JCM.02321-20

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  32 in total

1.  Unexpected long-lasting anti-HEV IgM positivity: Is HEV antigen a better serological marker for hepatitis E infection diagnosis?

Authors:  Mar Riveiro-Barciela; Ariadna Rando-Segura; Ana Barreira-Díaz; Marta Bes; Sofía P Ruzo; Maria Piron; Josep Quer; Silvia Sauleda; Francisco Rodríguez-Frías; Rafael Esteban; María Buti
Journal:  J Viral Hepat       Date:  2020-03-11       Impact factor: 3.728

2.  EASL Clinical Practice Guidelines on hepatitis E virus infection.

Authors: 
Journal:  J Hepatol       Date:  2018-03-31       Impact factor: 25.083

3.  Detection of HEV antigen as a novel marker for the diagnosis of hepatitis E.

Authors:  Feng Zhang; Xiuhua Li; Zhuo Li; Tim J Harrison; Huihui Chong; Shan Qiao; Weijin Huang; Huayuan Zhang; Hui Zhuang; Youchun Wang
Journal:  J Med Virol       Date:  2006-11       Impact factor: 2.327

4.  Hepatitis E Virus (HEV) ORF2 Antigen Levels Differentiate Between Acute and Chronic HEV Infection.

Authors:  Patrick Behrendt; Birgit Bremer; Daniel Todt; Richard J P Brown; Albert Heim; Michael P Manns; Eike Steinmann; Heiner Wedemeyer
Journal:  J Infect Dis       Date:  2016-05-27       Impact factor: 5.226

Review 5.  Hepatitis E: an emerging infection in developed countries.

Authors:  Harry R Dalton; Richard Bendall; Samreen Ijaz; Malcolm Banks
Journal:  Lancet Infect Dis       Date:  2008-11       Impact factor: 25.071

6.  Hepatitis E virus and chronic hepatitis in organ-transplant recipients.

Authors:  Nassim Kamar; Janick Selves; Jean-Michel Mansuy; Leila Ouezzani; Jean-Marie Péron; Joëlle Guitard; Olivier Cointault; Laure Esposito; Florence Abravanel; Marie Danjoux; Dominique Durand; Jean-Pierre Vinel; Jacques Izopet; Lionel Rostaing
Journal:  N Engl J Med       Date:  2008-02-21       Impact factor: 91.245

Review 7.  The role of hepatitis E virus testing in drug-induced liver injury.

Authors:  H R Dalton; H J Fellows; W Stableforth; M Joseph; P H Thurairajah; U Warshow; S Hazeldine; R Remnarace; S Ijaz; S H Hussaini; R P Bendall
Journal:  Aliment Pharmacol Ther       Date:  2007-09-07       Impact factor: 8.171

8.  Incidence and severity of viral hepatitis in pregnancy.

Authors:  M S Khuroo; M R Teli; S Skidmore; M A Sofi; M I Khuroo
Journal:  Am J Med       Date:  1981-02       Impact factor: 4.965

Review 9.  Hepatitis E: an underestimated emerging threat.

Authors:  Glynn W Webb; Harry R Dalton
Journal:  Ther Adv Infect Dis       Date:  2019-04-03

10.  Seroprevalence of hepatitis E virus infection, rural southern People's Republic of China.

Authors:  Rong-Cheng Li; Sheng-Xiang Ge; Yan-Ping Li; Ying-Jie Zheng; Yi Nong; Qing-Shun Guo; Jun Zhang; Mun-Hon Ng; Ning-Shao Xia
Journal:  Emerg Infect Dis       Date:  2006-11       Impact factor: 6.883

View more
  2 in total

1.  Epidemiological Characteristics and Clinical Manifestations of Hepatitis E in a Tertiary Hospital in China: A Retrospective Study.

Authors:  Li Fang; Junli Zhang; Huiying Chen; Fangfang Lv; Yunsong Yu; Xiaoxing Du
Journal:  Front Microbiol       Date:  2022-03-03       Impact factor: 5.640

2.  Hepatitis E virus as a trigger for Guillain-Barré syndrome.

Authors:  Miriam Fritz-Weltin; Estelle Frommherz; Nora Isenmann; Lisa Niedermeier; Benedikt Csernalabics; Tobias Boettler; Christoph Neumann-Haefelin; Dominique Endres; Marcus Panning; Benjamin Berger
Journal:  BMC Neurol       Date:  2021-08-06       Impact factor: 2.474

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.